We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Jazz Pharmaceuticals PLC | NASDAQ:JAZZ | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.49 | -3.09% | 109.63 | 107.10 | 180.00 | 113.84 | 109.32 | 113.15 | 564,155 | 05:00:13 |
By Denny Jacob
Avadel Pharmaceuticals intends to intervene in a lawsuit filed by Jazz Pharmaceuticals against the U.S. Food and Drug Administration, Avadel Chief Executive Greg Divis said.
Ireland-based biopharmaceutical company Jazz Pharmaceuticals said Thursday in a regulatory filing that its lawsuit alleges that the FDA acted outside its authority under the Orphan Drug Act when it approved Avadel's new drug application for Lumryz and granted it orphan drug exclusivity.
The lawsuit alleges the FDA acted without lawful basis when the agency determined that Lumryz boosted patient care and was purportedly clinically superior to two similar drugs that Jazz Pharmaceutical produces, Xywav and Xyrem.
Divis said that Avadel would "vigorously defend FDA's decisions to approve Lumryz and grant it orphan drug exclusivity, which were entirely proper under the law and rooted in the facts." He added that Lumryz launched earlier this month and is on track with expectations.
Jazz Pharmaceuticals said Xywav already had orphan drug exclusivity and described Lumryz as an extended-release reformulation of Xyrem. The drugs treat cataplexy, or excessive daytime sleepiness, in adults with narcolepsy.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
June 23, 2023 14:50 ET (18:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Jazz Pharmaceuticals Chart |
1 Month Jazz Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions